Roche Heat-Seq Target Enrichment Systems | GenomeWeb

Roche Heat-Seq Target Enrichment Systems

Aug 03, 2016

Roche has launched its Heat-Seq Target Enrichment Systems, which combines molecular inversion probe technology with molecular barcodes in a streamlined workflow to provide researchers with speed and reliability in analyzing sequence data. Molecular barcodes allow users to accurately measure how much sequence data came from the sample itself, how much data was unique, and how much data was redundant due to amplification during the PCR process — something traditional PCR-based methods can't provide, the company said.

More Like This

Mar 28, 2017

Bruker Avance Neo NMR Research Platform

Bruker has launched its  Avance Neo NMR Research Platform. The next-generation NMR electronics console surpasses the firm's previous Avance III HD, offering even faster control, improved dynamic range, and enhanced flexibility and scalability, Bruker said. New transceiver architecture enables each channel of the Avance Neo to operate as a fully functional spectrometer. According to the company, the new system also allows NMR pulse programs developed on previous Avance platforms, as well as new multi-receive pulse sequencing and experimental design capabilities never before available in the field.


Mar 27, 2017

Bioline JetSeq DNA Quantification Kits

Bioline, a wholly-owned subsidiary of Meridian Bioscience, has launched the JetSeq Library Quantification Kit. The qPCR-based assay provides fast, accurate, and sensitive quantification of adaptor-ligated DNA fragments during the preparation of Illumina-compatible NGS libraries.

The kit relies on SYBR Green for detection and contains all of the components required for library quantification, including dilution buffer, P5 and P7 adapter primers, and six pre-diluted DNA standards to minimize pipetting, reduce variability, and increase reproducibility. It has sufficient standards to quantify eighteen libraries on individual plates or up to seventy-six libraries when multiple libraries are quantified on the same plate.

Mar 27, 2017

10X Genomics Chromium Single Cell V(D)J Solution

10X Genomics has launched a high-throughput solution for profiling paired V(D)J transcripts from hundreds to millions of lymphocytes. The solution includes the necessary chemistry and microfluidics consumables, as well as a complete software suite, and it runs on the firm's Chromium Controller or Chromium Single Cell Controller microfluidics platforms. It will be useful to researchers in vaccine development, clonal immune cell dynamics, immune responses to checkpoint blockades, and the development of recombinant antibodies and engineered T cells used in immunotherapies for cancer and other diseases, the firm said. 

Mar 24, 2017

Cepheid Xpert MTB/RIF Ultra

Cepheid, Rutgers New Jersey Medical School and FIND launched the Xpert MTB/RIF Ultra test for diagnosing tuberculosis and resistance to the antibiotic rifampicin. The test is the second generation of Cepheid's Xpert MTB/RIF test, which was launched in 2010. The Ultra was redesigned to increase analytical sensitivity more than tenfold and to improve the detection of mutations associated with rifampin resistance, FIND said.

The World Health Organization recommends the new test be used as an alternative to the older test in all settings, but a WHO expert group also noted that because of the increased sensitivity, use of the Ultra can result in higher numbers of false positives, compared to Expert MTB/RIF. As a result, the group said more discussion is needed on implementing the new test and balancing increased sensitivity with decreased specificity in different settings.

The Ultra was developed by Cepheid in collaboration with Rutgers. Additional support was provided by the US National Institute of Allergy and Infectious Diseases, and FIND. The governments of Australia, the Netherlands, and the UK also provided funding. 

Mar 23, 2017

Seraseq Inherited Cancer DNA Mix Reference Material

SeraCare Life Sciences has launched multiplexed Seraseq Inherited Cancer DNA Mix reference material for inherited disease testing by next-generation sequencing. The mix is focused on seven genes associated with inherited cancer syndromes, including BRCA1 and BRCA2. It combines over 20 pathogenic variants of diverse types in well-characterized genomic background that can be used for assay development and analytical validation, the company said.

Mar 23, 2017

PierianDx Clinical Interpretation Services

PierianDx is launching clinical interpretation as part of its next-generation sequencing services portfolio. Customers will be able to select from a menu of options. Variant scientist review, conducted by PierianDx cancer biologists and genetics professionals, will provide variant classification and annotation. Medical director review, conducted by board-certified molecular pathologists and medical geneticists, will provide assessments of variants' medical significance, including recommended therapeutic options, disease monitoring, clinical trial enrollment, or genetic counseling. Options for direct consultation or participation on molecular tumor boards are also available. Sign-out services, conducted by PierianDx medical directors with the appropriate state licensures, will provide sign-out for cases previously reviewed by interpretation services.

Mar 23, 2017

Optra IPhronesis Knowledge Automation for Clinical Genomics Platform

Optra Health has launched iPhronesis Knowledge Automation for Clinical Genomics. The platform uses advanced natural language processing algorithms and deep machine learning in addition to the iPhronesis Cognitive Workbench to automate literature and data review. It includes data connectors to public databases, such ClinVar, and repositories, such as PubMed and OMIM. It includes an intuitive user interface and simple workflow so consumers can adopt the software quickly and efficiently, the company said.

Mar 23, 2017

Invitae Genetic Health Screen

Invitae has launched its Genetic Health Screen tests, an expansion of its offerings as part of the company's ongoing proactive genetic testing pilot program. The expansion includes additional genes linked to cancer, cardiovascular conditions and other genetic disorders and provides information on 139 medically actionable genes. The company also offers sub-panels focused only on cardiovascular conditions or cancer. The tests are intended for patients who do not meet diagnostic criteria for genetic testing, but who wish to use genetic information to help guide their health decisions, the company said. They can only be ordered by a physician.

Mar 23, 2017

Synthego CRISPRevolution Chemically Modified Synthetic sgRNAs

Synthego has announced new chemically modified synthetic single guide RNAs for CRISPR genome editing. The modified guides provide protection against intracellular immune responses in primary and stem cells and against exonuclease attack in both eukaryotic and prokaryotic cells. The sgRNAs are synthesized with 2'-O-methyl analogs and 3' phosphorothioate internucleotide linkages in the first three nucleotides at both the 5' and 3' end of the RNA molecule.

Mar 22, 2017

Genome Workbench 2.11.10

The National Center for Biotechnology Information has released Genome Workbench 2.11.10. This version of the platform includes critical improvement in HTTPs protocol communication with NCBI, improvements to the Graphical Sequence View, new manual for search in bio-trees, and numerous bug fixes and improvements.

Mar 22, 2017

Variantyx Genomic Intelligence Platform

Variantyx has launched its Genomic Intelligence platform. The platform automates the complete NGS testing process from sample collection to sequencing, data analysis, interpretation and clinical report generation. It utilizes public and the company's in-house resources to detect and report clinically actionable variants to consumers. The company is also offering to use the platform to review previously undiagnosed cases to provide a second opinion to clinicians at no cost, it said.

Mar 22, 2017

FDNA Face2Gene Research Application

FDNA has launched Face2Gene Research, an application that uses facial analysis, deep learning, and artificial intelligence to analyze patient cohorts to make clinical genomic discoveries. The application allows clinicians to de-identify medical data from their patients to discover syndrome phenotypes; compare phenotypes, genes, and gestalts among multiple cohorts; compare syndrome or gene cohorts to a normal population; expand data collection; and offer collaboration opportunities.

Mar 22, 2017

EntroGen Colorectal Cancer Panel, Thyroid Cancer Mutation and Fusion Gene Detection Kits

EntroGen has launched its Colorectal Cancer panel, Thyroid Cancer Mutation Analysis kit, and Thyroid Cancer Fusion Gene Detection kit. The panel is a PCR-based, highly multiplexed assay that allows consumers to screen or 50 somatic mutations in oncogenes associated with colorectal cancer tumors (KRAS, NRAS, BRAF, PIK3CA, and AKT). It is compatible with formalin fixed paraffin embedded and fresh frozen tissue. The Thyroid Cancer Mutation Analysis kit and Thyroid Cancer Fusion Gene Detection kit are multiplexed PCR-based assays that prevent unnecessary surgeries due to indeterminate cytology specimens, the company said. The mutation analysis kit detects point mutations in BRAF, KRAS, NRAS, and HRAS is isolated DNA. The fusion gene detection kit detects the chromosomal translocation RET/PTC1, and PAX8/PPARy in RNA. These kits are compatible with FFPE, fine needle aspiration, and fresh frozen samples. All three products have received the CE-IVD mark.

Mar 22, 2017

Invitae Spinal Muscular Atrophy Test

Invitae launched a new genetic test for diagnosing spinal muscular atrophy (SMA), a neuromuscular disease that impacts infants' ability to walk, crawl, and eventually breath and swallow, and can be lethal. The company claims that its genetic test is an improvement over currently available methods. Affecting one in every 10,000 infants, SMA is an autosomal recessive disorder that is usually caused by the loss of SMN1 gene, while variations in the number of copies of SMN2 contributes to disease severity. Accurately gauging both sequence changes in SMN1 and copy number changes in SMN2 has been challenging in the past, but the company said in a statement it is hoping to address this with its next-generation sequencing test and customized bioinformatics solution. Invitae is offering analysis of SMN1 and SMN2 as a standalone test, and adding the genes to its neuromuscular and neuropathy panels.

Mar 21, 2017

Agilent SureSelect Clinical Research Exome V2

Agilent Technologies has introduced a new target enrichment technology for next-generation sequencing. The SureSelect Clinical Research Exome V2 adds coverage for 1,099 additional disease-relevant targets, 75,000 splice sites of noncoding exons, more than 12,000 deep intronic variants, and more than 800 variants in promoter regions. The targets were curated in collaboration with Emory University and the Children's Hospital of Philadelphia.

The White House has created a list of cuts, including to the NIH, that could be in a budget bill for this year.

The US National Institutes of Health is to allow applicants to cite preprints just as they would any other research paper, ScienceInsider reports.

Two manuscript pages handwritten by Charles Darwin are going on the auction block, according to the Los Angeles Times.

In PNAS this week: tool to track transcriptome-wide binding, evidence of balancing selection on behavior-linked genes, and more.

Mar
30
Sponsored by
SeraCare

Our roundtable of industry experts will provide an overview of the current regulatory landscape for clinical genomics tests.

Apr
13
Sponsored by
SeraCare

In this webinar, Gregory J. Tsongalis of Dartmouth Hitchcock Medical Center will discuss how his lab developed and validated a cancer hotspot assay. 

Apr
27
Sponsored by
SeraCare

This webinar is the third in a four-part series highlighting real-world examples of how some lab directors are bringing validated next-generation sequencing-based tests to the clinic.

May
09
Sponsored by
SeraCare

This webinar is the last in a four-part series highlighting real-world examples of how some lab directors are bringing validated next-generation sequencing-based tests to the clinic.